ArticleCell2005
A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint.
Article in Cell, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.
- p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.BMC medical genetics · 2020Pooled it
- Article
- The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer.International journal of molecular sciences · 2025Review
- Role of DEAD/DEAH-box helicases in immunity, infection and cancers.Cell communication and signaling : CCS · 2025Review
- Structural diversity of p63 and p73 isoforms.Cell death and differentiation · 2022Review
- Alternative Splicing in Cancer and Immune Cells.Cancers · 2022Review
- Review
- ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma.Cancer management and research · 2019Article
- CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27.Cell & bioscience · 2018Article
- A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer.Oncogene · 2017Article
- p53 signaling modulation of cell cycle arrest and viral replication in porcine circovirus type 2 infection cells.Veterinary research · 2016Article
- Wild-type p53 binds to MYC promoter G-quadruplex.Bioscience reports · 2016Article
- p21 participates in the regulation of anaplastic thyroid cancer cell proliferation by miR-146b.Oncology letters · 2016Article
- p53 Specifically Binds Triplex DNA In Vitro and in Cells.PloS one · 2016Article
- p53 suppresses CCL2-induced subcutaneous tumor xenograft.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- CTRP3 Stimulates Proliferation and Anti-Apoptosis of Prostate Cells through PKC Signaling Pathways.PloS one · 2015Article
- SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells.Oncotarget · 2014Article
- Identification of p53 and its isoforms in human breast carcinoma cells.TheScientificWorldJournal · 2014Article
- Mutant p53 protein expression and antioxidant status deficiency in breast cancer.EXCLI journal · 2014Article
- Uncovering the role of p53 splice variants in human malignancy: a clinical perspective.OncoTargets and therapy · 2013Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The archetypal human tumor suppressor p53 is considered to have unique transactivation properties. The assumption is based on the fact that additionally identified human p53 isoforms lack transcriptional activity. However, we provide evidence for the existence of an alternatively spliced p53 isoform (Deltap53) that exerts its transcriptional activity independent from p53. In contrast to p53, Deltap53 transactivates the endogenous p21 and 14-3-3sigma but not the mdm2, bax, and PIG3 promoter. Cell cycle studies showed that Deltap53 displays its differential transcriptional activity only in damaged S phase cells. Upon activation of the ATR-intra-S phase checkpoint, Deltap53, but not p53, transactivates the Cdk inhibitor p21. Induction of p21 results in downregulation of cyclin A-Cdk activity and accordingly attenuation of S phase progression. Data demonstrate that the Deltap53-p21-cyclin A-Cdk pathway is crucial to facilitate uncoupling of repair and replication events, indicating that Deltap53 is an essential element of the ATR-intra-S phase checkpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.